Fortune unveiled its 2025 China Tech 50 list on August 21, with Zhongshan-based Akeso Inc securing a spot for the first time as the city's sole representative.

Guangdong province has 14 companies on the list, spanning electrocommunication, smart manufacturing, internet services and biopharmaceuticals. 

Fortune editors highlighted Akeso as a rare Chinese biopharma innovator possessing a fully integrated, independently developed system for drug discovery, manufacturing and commercialization.

The company operates an end-to-end R&D platform and ranks among China's top developers of innovative antibody drugs, maintaining one of the country's most robust pipelines.

Currently, Akeso has commercialized 7 new drugs, and it is the world's only pharmaceutical firm with 2 approved bispecific antibody drugs for tumor immunotherapy.